Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis.
Thomas MF, Slowikowski K, Manakongtreecheep K, Sen P, Samanta N, Tantivit J, Nasrallah M, Zubiri L, Smith NP, Tirard A, Ramesh S, Arnold BY, Nieman LT, Chen JH, Eisenhaure T, Pelka K, Song Y, Xu KH, Jorgji V, Pinto CJ, Sharova T, Glasser R, Chan P, Sullivan RJ, Khalili H, Juric D, Boland GM, Dougan M, Hacohen N, Li B, Reynolds KL, Villani AC. Thomas MF, et al. Among authors: dougan m. Nat Med. 2024 May;30(5):1349-1362. doi: 10.1038/s41591-024-02895-x. Epub 2024 May 9. Nat Med. 2024. PMID: 38724705 Free PMC article.
IAP inhibitors enhance co-stimulation to promote tumor immunity.
Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, Draganov D, Goyal G, Li W, Neuberg D, Blumberg R, Hacohen N, Porter D, Zawel L, Dranoff G. Dougan M, et al. Among authors: dougan s. J Exp Med. 2010 Sep 27;207(10):2195-206. doi: 10.1084/jem.20101123. Epub 2010 Sep 13. J Exp Med. 2010. PMID: 20837698 Free PMC article.
Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study.
Molina GE, Allen IM, Hughes MS, Zubiri L, Lee H, Mooradian MJ, Reynolds KL, Dougan M, Chen ST. Molina GE, et al. Among authors: dougan m. J Am Acad Dermatol. 2020 Mar;82(3):743-746. doi: 10.1016/j.jaad.2019.07.049. Epub 2019 Jul 23. J Am Acad Dermatol. 2020. PMID: 31349048 Free PMC article. No abstract available.
Diagnosis and Management of Rare Immune-Related Adverse Events.
Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL. Schoenfeld SR, et al. Among authors: dougan m. Oncologist. 2020 Jan;25(1):6-14. doi: 10.1634/theoncologist.2019-0083. Epub 2019 Nov 6. Oncologist. 2020. PMID: 31694890 Free PMC article.
Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy.
Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Zubiri L, et al. Among authors: dougan m. Oncologist. 2020 Mar;25(3):e398-e404. doi: 10.1634/theoncologist.2018-0883. Epub 2019 Nov 21. Oncologist. 2020. PMID: 32162817 Free PMC article.
177 results